Source: BioQ Pharma
SAN FRANCISCO and DUBAI, United Arab Emirates, April 04, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated, a specialty pharmaceutical company, and Lunatus, a company focused on building and developing profitable pharmaceutical brands in Arabian Gulf and Middle East markets, today announced the addition of a third ready-to-use infusible pharmaceutical product to their existing strategic distribution, supply, and commercial agreement. Adding this third drug expands BioQ Pharma and Lunatus’ previously signed agreement covering ropivacaine and propofol infusion pharmaceutical products in Saudi Arabia, the United Arab Emirates, Qatar and Kuwait.
Josh Kriesel, President and CEO of BioQ Pharma, remarked, "We are extremely pleased to expand our commercial partnership with Lunatus in the Gulf to three of our proprietary infusion pharmaceuticals. Lunatus’ commercial expertise in the region is invaluable as we jointly expand our product offerings."
Dr. Lina Kouatly, President and CEO of Lunatus, added, "We are excited to grow our collaboration with BioQ Pharma as we now prepare to introduce a third unit-dose infusion pharmaceutical in the Gulf region. These innovative ready-to-use products offer significant utility to our customers and patients by alleviating much of the onus inherent in delivering traditional drug infusions."
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, Galen Limited, and West Pharmaceutical Services.
Since its inception in 2003, Lunatus has established a successful track record in introducing, building and developing profitable brands in the fields of pharmaceutical, RX & OTC, aesthetic medicine & skin care, consumer health and medical equipment for international healthcare companies in the Arabian Gulf and Middle East markets. The Company’s mission is to provide value added marketing and operational services tailored to the versatility of the region. Lunatus partners with wide array of healthcare companies and corresponding brands including Valeant, Mylan, Merz Aesthetics, Omega Pharma, SoftFil, Opko Lab, Lumenis, BSN Medical, Ferris MFG. Corp. and IPRAD Laboratories. For more details about Lunatus Marketing and Consultancy please visit www.lunatus-me.com or email email@example.com.
Company Contact Information: Josh Kriesel BioQ Pharma President and CEO +1-415-336-6496 Ron Pauli BioQ Pharma Chief Financial Officer +1-415-889-7707 Walter Cleymans BioQ Pharma Chief Commercial Officer Phone: +32 474 (053) 253 Lina Kouatly Lunatus President and CEO Phone: +971 4 3405991/3 Media: Stephanie Carrington Integrated Corporate Relations, Inc. (ICR) +1-646-277-1282
Retrieved from "http://globenewswire.com/news-release/2017/04/04/954104/0/en/BioQ-Pharma-and-Lunatus-Add-a-Third-Infusion-Pharmaceutical-to-Commercial-Agreement-Covering-Arabian-Gulf-Area-and-Middle-East.html"